Developability Index: A Rapid In Silico Tool for the Screening of Antibody Aggregation Propensity, by Dr Bernhard Helk, #Norvatis

Speaking on the above topic is Dr Bernhard Helk, Global Executive Director, Technology Development, Novartis, Switzerland. He will be speaking at Biologic Manufacturing World Asia 2012, part of a series of conferences in the 5th Annual BioPharma Asia Convention 2012, held on 19-22 March at Marina Bay Sands, Singapore.

Dr Bernhard Helk is Global Executive Director of Technology Development at Novartis Biologics/Process Sciences. He received a masters degree in Pharmaceutical Sciences from University of Erlangen/Germany and a Ph. D. in Biochemistry from University of Bayreuth/Germany. He performed postdoctoral research with Prof. U.L. RajBhandary at MIT. At Novartis, Dr Helk has held positions of increasing responsibility in the area of analytics and development of therapeutic proteins. His research interest includes folding, purification, characterization, and stabilization of proteins. Currently, Dr. Helk is leading a unit that searches and evaluates new technologies related to manufacturing and formulation of proteins for pharmaceutical applications. He is also leading several collaborations with industrial and academic partners aimed at the development of disruptive new technologies.

Issues that Dr Helk will be addressing are as follows:
1. Evaluating current methods for in silico prediction of aggregation propensities
2. Developing a new technology: SAP (Spatial Aggregation Propensity) technology by Novartis and MIT
3. Mapping the possible applications of the SAP technology and demonstrating its use in protein engineering and in designing antibody drug conjugates

If you are keen to find out more, join us at BioPharma Asia Convention 2012 to gain valuable insights from more than 200 experts. Contact us now for more details!